The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.k

Sarcoid-like granulomatosis (endo-/extrathoracic)

Publications

Soto F, Torre-Sada LF, Mott FE, Kim ST, Nurieva R, Shannon VR, Faiz SA, Casal RF, Altan M, Lin J, Sheshadri A

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.

Journal of immunotherapy and precision oncology. 2023;6(2):111-116

Fakhri G, Akel R, Salem Z, Tawil A, Tfayli A

Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report.

Case reports in oncology. 2017;10(3):1070-1075

Yatim N, Mateus C, Charles P

Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.

La Revue de medecine interne. 2018;39(2):130-133

Al-Dliw M, Megri M, Shahoub I, Sahay G, Limjoco TI, Shweihat Y

Pembrolizumab reactivates pulmonary granulomatosis.

Respiratory medicine case reports. 2017;22:126-129

Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R

Pembrolizumab-associated sarcoidosis.

JAAD case reports. 2016;2(4):290-3

Cousin S, Toulmonde M, Kind M, Cazeau AL, Bechade D, Coindre JM, Italiano A

Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.

Annals of oncology : official journal of the European Society for Medical Oncology. 2016;27(6):1178-1179